Roche and Wellthy Therapeutics present evidence of improved diabetes care outcomes when patients engage with a digital therapeutic

June 18, 2019
Digital Transformation More...
Partnership More...
13275 thumb square
by Nardev Ramanathan
Very important

Roche and Wellthy Therapeutics partnered last year to test self-management practices for Type 2 diabetes using Roche's Accu-Chek and Wellthy's digital therapeutic (DTx). The study found that those with the highest engagement with Wellthy's DTx saw the largest reduction in blood sugar levels. The results were especially encouraging because they were found in a real-world setting, as opposed to a clinical trial setting. Roche has moved quickly to build a digital diabetes management ecosystem in a resource-constrained and low-health-literacy market. This is a great example of a foreign multinational tailoring its approach to fit local market needs and partnering with a local startup that's well-placed to understand local consumer behavior. 

For the original news article, click here .

Further Reading

U.S. FDA approves first digital inhaler that can be paired to a mobile app

News Commentary | January 2, 2019

Teva recently received marketing approval from the U.S. FDA for its ProAir Digihaler. The device is indicated for the treatment and prevention of obstructive airway diseases like asthma. A key challenge today for physicians is knowing if their patients are using their inhaled medication as intended... Not part of subscription

Roche Diabetes Care India launches Integrated Diabetes Management Solutions (IDMS), seeking to simplify diabetes management

Case Study | May 10, 2019

Diabetes is one of the most expensive chronic diseases to manage today. In India, diabetes is officially the fastest‑growing disease. There are more than 70 million Type 2 diabetics, and the number is expected to double by 2025. Interestingly, robust clinical intervention plans exists to manage ... Not part of subscription

Medtronic insulin pumps show a decrease in preventable hospital admissions in a study with UnitedHealthcare

News Commentary | July 19, 2018

The data is drawn from the first year of an ongoing pilot that started in 2016 and has shown a 27% lower rate of preventable hospital admissions over patients relying on multiple daily injections of insulin. Medtronic's insulin pump delivers basal insulin every five minutes based on real‑time sensor... Not part of subscription